Literature DB >> 12419482

High-density lipoproteins and atherosclerosis.

Daniel J Rader1.   

Abstract

High-density lipoproteins (HDLs) are strongly related to risk of atherosclerotic cardiovascular disease. Low levels of HDL cholesterol are a major cardiovascular risk factor, and overexpression of the major HDL protein, apolipoprotein (apo) A-I, markedly inhibits progression and even induces regression of atherosclerosis in animal models. Clinical data regarding the effect of increasing HDL cholesterol on vascular events are limited. HDL remains an important potential target for therapeutic intervention. A variety of gene products are involved in the regulation of HDL metabolism. Yet, the mechanisms by which HDL inhibits atherosclerosis are not yet fully understood. There remains much to be learned about HDL metabolism and its relation to atherosclerosis and other cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12419482     DOI: 10.1016/s0002-9149(02)02635-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  26 in total

1.  Is regression of coronary atherosclerosis possible by infusing recombinant apolipoprotein A-I?

Authors:  Robert A Hegele
Journal:  CMAJ       Date:  2004-03-16       Impact factor: 8.262

2.  Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice.

Authors:  Mary G Sorci-Thomas; Manal Zabalawi; Manish S Bharadwaj; Ashley J Wilhelm; John S Owen; Bela F Asztalos; Shaila Bhat; Michael J Thomas
Journal:  Biochim Biophys Acta       Date:  2011-09-14

Review 3.  Anti-inflammatory properties of HDL.

Authors:  Benjamin J Ansell; Mohamad Navab; Karol E Watson; Gregg C Fonarow; Alan M Fogelman
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

4.  Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis.

Authors:  V P van Halm; J C van Denderen; M J L Peters; J W R Twisk; M van der Paardt; I E van der Horst-Bruinsma; R J van de Stadt; M H M T de Koning; B A C Dijkmans; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2006-04-27       Impact factor: 19.103

5.  Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT.

Authors:  Kyriakos E Kypreos; Vassilis I Zannis
Journal:  Biochem J       Date:  2007-04-15       Impact factor: 3.857

Review 6.  Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis.

Authors:  V F Azevedo; R Pecoits-Filho
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

7.  Effect of Daisaikoto on Expressions of SIRT1 and NF-kappaB of Diabetic Fatty Liver Rats Induced by High-Fat Diet and Streptozotocin.

Authors:  Weibin Qian; Xinrui Cai; Xinying Zhang; Yingying Wang; Qiuhai Qian; Junichi Hasegawa
Journal:  Yonago Acta Med       Date:  2016-06-29       Impact factor: 1.641

8.  A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women.

Authors:  Viktor Hamrefors; Marju Orho-Melander; Ronald M Krauss; Bo Hedblad; Peter Almgren; Göran Berglund; Olle Melander
Journal:  J Lipid Res       Date:  2009-09-22       Impact factor: 5.922

9.  31st g. Heiner sell lectureship: secondary medical consequences of spinal cord injury.

Authors:  William A Bauman; Mark A Korsten; Miroslav Radulovic; Gregory J Schilero; Jill M Wecht; Ann M Spungen
Journal:  Top Spinal Cord Inj Rehabil       Date:  2012

10.  Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites.

Authors:  Seth S Martin; Atif N Qasim; Nehal N Mehta; Megan Wolfe; Karen Terembula; Stanley Schwartz; Nayyar Iqbal; Mark Schutta; Roshanak Bagheri; Muredach P Reilly
Journal:  Diabetes       Date:  2009-06-02       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.